Tazemetostat for treating relapsed or refractory
follicular lymphoma after two therapies

Tazemetostat is in clinical development for the treatment of adult patients with relapsed or
refractory follicular lymphoma who have received at least two prior treatments. Follicular
lymphoma is a cancer of a type of white blood cell called B lymphocytes, or B cells. In follicular
lymphoma, B cells multiply quickly and live for too long, so there are too many of them in the
lymph nodes. The first sign of the disease is usually a lump in the neck, under the arm or in the
groin area, caused by an enlarged lymph node. Patients may also have fever, weight loss,
tiredness, and night sweats. If a person has successful treatment but the follicular lymphoma
returns after more than six months, this is known as relapsed lymphoma, while if it returns within
six months, it is known as refractory lymphoma. Most patients will experience relapse and
subsequent treatments are not as efficient nor well tolerated as the first ones, hence the need for
more effective treatment options for the relapsed or refractory disease.